I won't publicly state how I really feel about Woodcock and Fauci, however, now that Amarex's failures have been brought to light and they are out of the picture, perhaps Leronlimab will be taken more seriously by the FDA?

I am encouraged to hear that the FDA has allowed meta analysis of our covid trials, meaning they will consider data from overseas sources, and our smaller trials. I am hopeful that with new CRO's and Recknor on the team the data can be compiled and presented in a meaningful and significant way.